Grace Therapeutics, Inc. (GRCE)
About Grace Therapeutics, Inc.
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.
Financial summary
- Revenue FY2022
- $100.0M
- Net income
- -$9.6M
- Total assets
- $72.0M
- Market cap
- $37.9M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Operating income
- -$11.1M
- Income tax
- -$1.7M
- Net income
- -$7.8M
- EPS (basic)
- $-0.47
- EPS (diluted)
- $-0.47
Balance sheet
- Total assets
- $66.7M
- Current assets
- $17.4M
- Total liabilities
- $2.8M
- Current liabilities
- $2.1M
- Shareholders’ equity
- $63.9M
Cash flow
- Operating cash flow
- -$8.9M
- Investing cash flow
- $5.2M
- Financing cash flow
- $3.7M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $37.9M
- EPS (diluted)
- $-0.47
- Shares outstanding
- 17.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 26, 2011
Grace Therapeutics, Inc. (GRCE) Stock Price
- Reported a net loss of $9.6M in FY2022.
- Trading 58% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Grace Therapeutics, Inc..
Write a review
News about Grace Therapeutics, Inc.
News & sentiment via Polygon.io
Grace Therapeutics, Inc.: frequently asked questions
Is Grace Therapeutics, Inc. an American company?
Grace Therapeutics, Inc. is a US-based company headquartered in Princeton, New Jersey, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Grace Therapeutics, Inc. headquartered?
Grace Therapeutics, Inc. is headquartered in Princeton, New Jersey, United States.
Is Grace Therapeutics, Inc. publicly traded?
Yes — Grace Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol GRCE on the NASDAQ.
What does Grace Therapeutics, Inc. do?
Grace Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
